For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
New this year at the CCTG Spring Meeting is an open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday 28 at 10:30 in the Wren room at the Chelsea Hotel.
Participants are invited to discuss and assess the Investigator and Patient perspective in patient-centred clinical trials. There will be an exploration of the CCTG Patient Engagement Model and an assessment of the clinical trial lifecycle identifying touch points to engage patients.
To ensure the security and safety of National Cancer Institute (NCI) systems, subjects, research staff, and all associated sensitive information, NCI introduced an identity verification system to access to the Cancer Therapy Evaluation Program (CTEP) and the Cancer Trails Support Unit (CTSU) websites in accordance with the Federal Information Security Management Act(FISMA) in July 2022. This new process uses ID.me, and requires completion of Identity Proofing (IP) and establishment of a Multi Factor Authentication (MFA) method as part of the registration process.
Canadian Cancer Society announces details of research funding for low-survival cancers, the CCTG Breakthrough Grant Application lead by Dr Marshall Pitz, has received $ 1,549,130 over 5 years.
The CO29 trial: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Sutdy, AGITG DYNAMIC-III has closed to accrual. The study reached its overall accrual target of 1000 patients, 209 of which were randomized by Canadian sites.
The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution.
Mark your calendars! Dr Lillian Siu is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting on Saturday April 29, 5:00 pm in the Mountbatten Room at the Chelsea Hotel in Toronto. Dr Siu's lecture is titled "Precision Cancer Medicine Beyond Next Generation Sequencing Gene Panels". This session is RCPSC accredited
About Dr Lillian Siu
